Cellectis CLLS
NASDAQ CLLS
$1.40 -0.11 (-7.28%)
At close: Oct 1, 2026 · 4:00 PM EDT

Cellectis (CLLS) Liabilities and Shareholders Equity (2013 - 2026)

Updated

Cellectis' Liabilities and Shareholders Equity came in at $267.37 million for Q2 2026, down 24.5% from $353.97 million a year earlier and down 7.5% from the prior quarter.

Analysis

Cellectis (CLLS) Liabilities and Shareholders Equity (2013 - 2026) Analysis & Trends

At the end of FY2025, Cellectis' Liabilities and Shareholders Equity was $324.72 million, down 15.3% from FY2024.

  • Liabilities and Shareholders Equity carries a five-year compound annual growth rate of -7.1% (FY2020 to FY2025).
  • Going back by year, Liabilities and Shareholders Equity was $383.54 million in FY2024 (+14.7%), $334.27 million in FY2023 (+28.0%), $261.22 million in FY2022 (-31.6%) and $382.08 million in FY2021 (-18.6%).
  • The Q2 2026 figure represents the lowest quarterly Liabilities and Shareholders Equity since Q3 2023.
  • Year-over-year, Liabilities and Shareholders Equity has declined for five consecutive quarters, with growth averaging 2.4% over the last eight quarters.
  • The fastest year-over-year change in Liabilities and Shareholders Equity over five years came in Q3 2024 (growth of 88.8%), and the weakest in Q3 2022 (a decline of 32.3%).
  • Business Quant data shows CLLS's Liabilities and Shareholders Equity at $289.19 million (Q1 2026), $324.72 million (Q4 2025) and $343.05 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 201.06 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 135.12 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 115.83 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 49.36 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 201.13 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 27.42 Bn
10 Cellectis 151.51 Mn -601.88 Mn - 267.37 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 267.37 Mn
Mar 31, 2026 289.19 Mn
Dec 31, 2025 324.72 Mn
Sep 30, 2025 343.05 Mn
Jun 30, 2025 353.97 Mn
Mar 31, 2025 364.09 Mn
Dec 31, 2024 383.54 Mn
Sep 30, 2024 395.88 Mn
Jun 30, 2024 407.15 Mn
Mar 31, 2024 354.46 Mn
Dec 31, 2023 334.27 Mn
Sep 30, 2023 209.70 Mn
Jun 30, 2023 227.67 Mn
Mar 31, 2023 251.41 Mn
Dec 31, 2022 261.22 Mn
Sep 30, 2022 279.58 Mn
Jun 30, 2022 320.88 Mn
Mar 31, 2022 347.19 Mn
Dec 31, 2021 382.08 Mn
Sep 30, 2021 412.89 Mn
API Access

Cellectis Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=CLLS&period=max&api_key=YOUR_API_KEY